<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35574241</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">2352-5789</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>41</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Gynecologic oncology reports</Title>
          <ISOAbbreviation>Gynecol Oncol Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Clear cell adenocarcinoma arising from anterior abdominal wall cesarean section scar endometriosis treated with excision and the addition of Trastuzumab for adjuvant chemotherapy: A case report.</ArticleTitle>
        <Pagination>
          <StartPage>100995</StartPage>
          <MedlinePgn>100995</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">100995</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.gore.2022.100995</ELocationID>
        <Abstract>
          <AbstractText>Abdominal wall endometriosis with subsequent transformation to clear cell carcinoma is quite rare. The pathogenesis and pattern of this transformation is not well known; hence evaluation and management guidelines are not well established. We highlight a case of clear cell adenocarcinoma arising from the anterior abdominal wall in a previous cesarean section scar treated with excision and the unique addition of Trastuzumab for adjuvant chemotherapy.</AbstractText>
          <CopyrightInformation>© 2022 The Authors.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lewis</LastName>
            <ForeName>Gregory K</ForeName>
            <Initials>GK</Initials>
            <AffiliationInfo>
              <Affiliation>Mayo Clinic Department of Medical and Surgical Gynecology, Mayo Clinic, Jacksonville, FL, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gajarawala</LastName>
            <ForeName>Shilpa N</ForeName>
            <Initials>SN</Initials>
            <AffiliationInfo>
              <Affiliation>Mayo Clinic Department of Medical and Surgical Gynecology, Mayo Clinic, Jacksonville, FL, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Robinson</LastName>
            <ForeName>Kyle E</ForeName>
            <Initials>KE</Initials>
            <AffiliationInfo>
              <Affiliation>Mayo Clinic Department of Medical and Surgical Gynecology, Mayo Clinic, Jacksonville, FL, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Anita H</ForeName>
            <Initials>AH</Initials>
            <AffiliationInfo>
              <Affiliation>Mayo Clinic Department of Medical and Surgical Gynecology, Mayo Clinic, Jacksonville, FL, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Robertson</LastName>
            <ForeName>Matthew W</ForeName>
            <Initials>MW</Initials>
            <AffiliationInfo>
              <Affiliation>Mayo Clinic Department of Medical and Surgical Gynecology, Mayo Clinic, Jacksonville, FL, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Gynecol Oncol Rep</MedlineTA>
        <NlmUniqueID>101652231</NlmUniqueID>
        <ISSNLinking>2352-5789</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Anterior abdominal wall</Keyword>
        <Keyword MajorTopicYN="N">Cesarean section scar</Keyword>
        <Keyword MajorTopicYN="N">Clear cell carcinoma</Keyword>
        <Keyword MajorTopicYN="N">Endometriosis</Keyword>
        <Keyword MajorTopicYN="N">Trastuzumab</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>16</Day>
          <Hour>4</Hour>
          <Minute>39</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35574241</ArticleId>
        <ArticleId IdType="pmc">PMC9096664</ArticleId>
        <ArticleId IdType="doi">10.1016/j.gore.2022.100995</ArticleId>
        <ArticleId IdType="pii">S2352-5789(22)00075-3</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Bookman M.A., Darcy K.M., Clarke-Pearson D., Boothby R.A., Horowitz I.R. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J. Clin. Oncol. 2003;21(2):283–290.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12525520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clamp A.R., James E.C., McNeish I.A., Dean A., Kim J.-W., O'Donnell D.M., Hook J., Coyle C., Blagden S., Brenton J.D., Naik R., Perren T., Sundar S., Cook A.D., Gopalakrishnan G.S., Gabra H., Lord R., Dark G., Earl H.M., Hall M., Banerjee S., Glasspool R.M., Jones R., Williams S., Swart A.M., Stenning S., Parmar M., Kaplan R., Ledermann J.A. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet. 2019;394(10214):2084–2095.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6902268</ArticleId>
            <ArticleId IdType="pubmed">31791688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fader A.N., Roque D.M., Siegel E., Buza N., Hui P., Abdelghany O., Chambers S.K., Secord A.A., Havrilesky L., O’Malley D.M., Backes F., Nevadunsky N., Edraki B., Pikaart D., Lowery W., ElSahwi K.S., Celano P., Bellone S., Azodi M., Litkouhi B., Ratner E., Silasi D.-A., Schwartz P.E., Santin A.D. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. J. Clin. Oncol. 2018;36(20):2044–2051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29584549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrandina G., Palluzzi E., Fanfani F., Gentileschi S., Valentini A.L., Mattoli M.V., Pennacchia I., Scambia G., Zannoni G. Endometriosis-associated clear cell carcinoma arising in caesarean section scar: a case report and review of the literature. World J. Surg. Oncol. 2016;14(1) doi: 10.1186/s12957-016-1054-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12957-016-1054-7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fleming G.F., Sill M.W., Darcy K.M., McMeekin D.S., Thigpen J.T., Adler L.M., Berek J.S., Chapman J.A., DiSilvestro P.A., Horowitz I.R., Fiorica J.V. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 2010;116(1):15–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2804260</ArticleId>
            <ArticleId IdType="pubmed">19840887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giannella L., Serri M., Maccaroni E., Di giuseppe J., Carpini G.D., Berardi R., Sopracordevole F., Ciavattini A. Endometriosis-associated Clear Cell Carcinoma of the Abdominal Wall After Caesarean Section: A Case Report and Review of the Literature. In Vivo. 2020;34(4):2147–2152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7439887</ArticleId>
            <ArticleId IdType="pubmed">32606196</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guastalla J.P., Allouache D., Combe M., Weber B., Cretin J., Curé H., Mousseau M., Paraiso D., Camilleri-Broët S., Pujade-Lauraine E. HER2 overexpression and amplification in advanced ovarian cancer (AOC): Treatment with trastuzumab—A GINECO study. J. Clin. Oncol. 2007;25(18_suppl)</Citation>
        </Reference>
        <Reference>
          <Citation>Jewell E., Secord A.A., Brotherton T., Berchuck A. Use of trastuzumab in the treatment of metastatic endometrial cancer. Int. J. Gynecol. Cancer. 2006;16(3):1370–1373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16803532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marques C., Silva T.S., Dias M.F. Clear cell carcinoma arising from abdominal wall endometriosis - Brief report and review of the literature. Gynecol. Oncol. Rep. 2017;20:78–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5362132</ArticleId>
            <ArticleId IdType="pubmed">28367489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pignata S., Scambia G., Katsaros D., Gallo C., Pujade-Lauraine E., De Placido S., Bologna A., Weber B., Raspagliesi F., Panici P.B., Cormio G., Sorio R., Cavazzini M.G., Ferrandina G., Breda E., Murgia V., Sacco C., Cinieri S., Salutari V., Ricci C., Pisano C., Greggi S., Lauria R., Lorusso D., Marchetti C., Selvaggi L., Signoriello S., Piccirillo M.C., Di Maio M., Perrone F. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2014;15(4):396–405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24582486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Safra T., Waissengrin B., Levy T., Leidner E., Merose R., Matceyevsky D., Grisaru D., Laskov I., Mishaan N., Shayzaf R., Wolf I. Weekly Carboplatin and Paclitaxel: A Retrospective Comparison with the Three-Weekly Schedule in First-Line Treatment of Ovarian Cancer. Oncologist. 2021;26(1):30–39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7794189</ArticleId>
            <ArticleId IdType="pubmed">32657524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santin A.D., Bellone S., Roman J.J., McKenney J.K., Pecorelli S. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int. J. Gynaecol. Obstet. 2008;102(2):128–131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18555254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stevens E.E., et al.  Malignant transformation of endometriosis in a cesarean section abdominal wall scar: a case report. J. Reprod. Med. 2013;58(5–6):264–266.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23763014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thouvenin L., et al.  Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab. Gynecol. Oncol. Rep. 2021;37</Citation>
        </Reference>
        <Reference>
          <Citation>Wei C.J., Huang S.H. Clear cell carcinoma arising from scar endometriosis: A case report and literature review. Ci Ji Yi Xue Za Zhi. 2017;29(1):55–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5509184</ArticleId>
            <ArticleId IdType="pubmed">28757766</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
